| Ticker | RLAY |
|---|---|
| ISIN | US75943R1023 |
| Sector | Atención sanitaria |
| Industria | Biotechnology |
| Mercado | NASDAQ |
| Capitalización | $2.246.583.419 |
| Beta | 1,58 |
| Sitio web | https://www.relaytx.com |
| CEO | Sanjiv K. Patel |
| Fecha de IPO | 16/07/2020 |
| País | US |
| Dirección | 399 Binney Street, Cambridge, MA, 02139 |
| Volumen | 3.646.132 |
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altere...
El precio actual de Relay Therapeutics, Inc. (RLAY) es de 12,57, con una variación del -3,53%.
Relay Therapeutics, Inc. opera en el sector Healthcare, industria Biotechnology.
Compara brokers con acceso a las principales bolsas internacionales, con bajas comisiones, custodia y herramientas de análisis para invertir en acciones.
Compara brokers para acciones